Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Acumen Pharmaceuticals (NASDAQ:ABOS) from a sell rating to a hold rating in a research note issued to investors on Sunday.

A number of other equities research analysts have also recently issued reports on the stock. BTIG Research reissued a “buy” rating and set a $8.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.67.

Acumen Pharmaceuticals Price Performance

Acumen Pharmaceuticals stock opened at $2.26 on Friday. The company has a market capitalization of $163.19 million, a PE ratio of -1.12 and a beta of 0.20. Acumen Pharmaceuticals has a 12-month low of $0.86 and a 12-month high of $3.60. The firm’s fifty day moving average is $2.70 and its 200 day moving average is $2.17. The company has a quick ratio of 4.07, a current ratio of 4.07 and a debt-to-equity ratio of 0.32.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.09. The company had revenue of ($0.09) million during the quarter. As a group, sell-side analysts predict that Acumen Pharmaceuticals will post -1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Daniel Joseph Oconnell sold 37,755 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the transaction, the chief executive officer owned 619,982 shares of the company’s stock, valued at approximately $1,233,764.18. This trade represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 149,818 shares of company stock valued at $285,057 over the last 90 days. 7.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several large investors have recently made changes to their positions in ABOS. Jacobs Levy Equity Management Inc. purchased a new position in shares of Acumen Pharmaceuticals in the 3rd quarter worth approximately $27,000. Marex Group plc purchased a new position in Acumen Pharmaceuticals in the 2nd quarter worth about $39,000. Independent Advisor Alliance bought a new stake in shares of Acumen Pharmaceuticals during the fourth quarter valued at approximately $40,000. PFG Investments LLC lifted its holdings in shares of Acumen Pharmaceuticals by 65.2% in the 4th quarter. PFG Investments LLC now owns 19,000 shares of the company’s stock worth $40,000 after buying an additional 7,500 shares during the period. Finally, Marshall Wace LLP purchased a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $44,000. 71.01% of the stock is owned by institutional investors.

More Acumen Pharmaceuticals News

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen said it has $36M of funding to advance its EBD program and is targeting an ALTITUDE‑AD Phase II readout in late 2026 — this provides program funding visibility and a clear clinical milestone that could re‑rate shares if results are favorable. Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set an $8 price target, suggesting sizable upside from current levels and giving institutional validation to the company’s clinical strategy. BTIG buy rating and $8 price target coverage
• Positive Sentiment: Q4 results beat on the EPS line (reported $(0.41) vs. $(0.50) consensus), showing a smaller-than-expected loss and suggesting modest operating leverage as programs advance. Acumen Q4 EPS beat and earnings materials
• Neutral Sentiment: Company press release and earnings‑call highlights outlined strategic advances and program updates (full-year financials and business highlights), which provide context but no immediate new financing or partnership decisions. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full-year 2025 financial report reiterates cash burn, program priorities and R&D focus — useful for modeling runway but not a catalyst by itself. Acumen reports financial results and business highlights
• Negative Sentiment: Acumen filed to sell 10.83 million shares of common stock on behalf of holders — a potential secondary that increases near‑term supply and dilution risk, which likely pressured the stock despite operational positives. Acumen files to sell 10.83M shares for holders

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.